Caulis, Inc. (JP:153A)
:153A
153A Stock Chart & Stats
¥2129.00
-¥52.00(-3.54%)
At close: 4:00 PM EST
¥2129.00
-¥52.00(-3.54%)
Day’s Range― - ―
52-Week Range¥688.00 - ¥2,888.00
Previous CloseN/A
Volume54.50K
Average Volume (3M)92.42K
Market Cap
¥9.20B
Enterprise Value¥7.19B
Total Cash (Recent Filing)¥1.88B
Total Debt (Recent Filing)¥250.00M
Price to Earnings (P/E)27.4
Beta1.35
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.88
Shares Outstanding6,530,800
10 Day Avg. Volume64,850
30 Day Avg. Volume92,423
Financial Highlights & Ratios
PEG Ratio-7.19
Price to Book (P/B)4.57
Price to Sales (P/S)5.41
P/FCF Ratio36.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 2025 revenue surge of ~108.9% signals strong product-market fit and scalable demand rather than a one-off spike. Sustained top-line momentum supports long-term investment in R&D and sales, enabling market-share gains and durable operating leverage as volumes normalize.
Profitability MarginsHigh 2025 margins (gross ~58%, operating ~29%, net ~20%) indicate structural pricing power and efficient cost structure versus peers. Such margins provide ongoing funding for growth initiatives, buffer against cyclical pressure, and underpin sustained return on invested capital.
De-risked Balance SheetMaterial reduction in leverage to D/E ~0.06 and healthy ROE imply a much stronger capital base and lower financial risk. This enhances flexibility for capital allocation, supports resilience through downturns, and makes future investments or acquisitions less balance-sheet constrained.
Bears Say
Margin CompressionMargins have compressed versus 2022–2024, implying rising cost pressure or pricing dilution as the business scales. Persistent compression would erode the firm’s attractive profitability profile, limiting free cash flow and reducing the durability of current return metrics.
Volatile Cash GenerationDespite strong reported profits, operating cash flow fell in 2025 and free cash flow declined in 2024–2025, with cash conversion near ~0.40. This cash volatility undermines reliability of internal funding for capex, dividends, or M&A and raises execution risk for growth plans.
Recent Historical Financial StressThe firm’s balance-sheet weakness in prior years (negative equity in 2021, high leverage in 2022) shows the recovery is recent. That history heightens sensitivity to setbacks: progress must be sustained or the company could face renewed funding or solvency pressure under adverse conditions.
153A FAQ
What was Caulis, Inc.’s price range in the past 12 months?
Caulis, Inc. lowest stock price was ¥688.00 and its highest was ¥2888.00 in the past 12 months.
What is Caulis, Inc.’s market cap?
Caulis, Inc.’s market cap is ¥9.20B.
When is Caulis, Inc.’s upcoming earnings report date?
Caulis, Inc.’s upcoming earnings report date is May 15, 2026 which is in 37 days.
How were Caulis, Inc.’s earnings last quarter?
Caulis, Inc. released its earnings results on Feb 13, 2026. The company reported ¥8.88 earnings per share for the quarter, beating the consensus estimate of N/A by ¥8.88.
Is Caulis, Inc. overvalued?
According to Wall Street analysts Caulis, Inc.’s price is currently Overvalued.
Does Caulis, Inc. pay dividends?
Caulis, Inc. pays a Notavailable dividend of ¥4.8 which represents an annual dividend yield of N/A. See more information on Caulis, Inc. dividends here
What is Caulis, Inc.’s EPS estimate?
Caulis, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caulis, Inc. have?
Caulis, Inc. has 6,530,800 shares outstanding.
What happened to Caulis, Inc.’s price movement after its last earnings report?
Caulis, Inc. reported an EPS of ¥8.88 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.985%.
Which hedge fund is a major shareholder of Caulis, Inc.?
Currently, no hedge funds are holding shares in JP:153A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Caulis, Inc.
Caulis, Inc. (153A) is a biotechnology company specializing in the development of innovative agricultural solutions and biopesticides aimed at enhancing crop productivity and sustainability. The company focuses on harnessing natural plant-based compounds and advanced biotechnological methods to create products that protect crops from pests and diseases while minimizing environmental impact. Caulis, Inc. operates primarily within the agricultural sector, catering to farmers and agricultural businesses seeking eco-friendly alternatives to traditional chemical pesticides.